p.75 抽出テキスト

CLINICAL STATEMENTS AND GUIDELINES

Circulation. 2024;149:e1313–e1410. DOI: 10.1161/CIR.0000000000001251 June 11, 2024 e1387

12 Suckow BD, Kraiss LW, Schanzer A, et al. Statin therapy after infrainguinal

bypass surgery for critical limb ischemia is associated with improved 5-year survival. J Vasc Surg. 2015;61:126–133. 13.	 Stavroulakis K, Borowski M, Torsello G, et al. Association between statin therapy and amputation-free survival in patients with critical limb ischemia in the CRITISCH registry. J Vasc Surg. 2017;66:1534–1542. 14.	 Foley TR, Singh GD, Kokkinidis DG, et al. High-intensity statin therapy is associated with improved survival in patients with peripheral artery disease. J Am Heart Assoc. 2017;6:e005699. 15.	 DeCarlo C, Scher L, Shariff S, et al. Statin use and other factors associated with mortality after major lower extremity amputation. J Vasc Surg. 2017;66:216–225. 16.	 Karlson BW, Wiklund O, Palmer MK, et al. Variability of low-density lipoprotein cholesterol response with different doses of atorvastatin, rosuvastatin, and simvastatin: results from VOYAGER. Eur Heart J Cardiovasc Pharmacother. 2016;2:212–217. 17.	 US Food and Drug Administration. Drugs@FDA: FDA Approved Drug Prod-

ucts [database]. Accessed March 1, 2021. https://www.accessdata.fda. gov/scripts/cder/daf/. 5.3. Antihypertensive Therapy for PAD 1.	 Piller LB, Simpson LM, Baraniuk S, et al. Characteristics and long-term follow-up of participants with peripheral arterial disease during ALLHAT. J Gen Intern Med. 2014;29:1475–1483. 2.	 Diehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens. 2011;29:1448–1456. 3.	 Paravastu SC, Mendonca DA, Da Silva A. Beta blockers for peripheral arterial disease. Cochrane Database Syst Rev. 2013;CD005508. 4.	 Espinola-Klein C, Weisser G, Jagodzinski A, et al. β-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58:148– 154. 5.	 Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13– e115. 6.	 Sprint Research Group, Wright JT Jr, Williamson JD, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116. 7.	 Bavry AA, Anderson RD, Gong Y, et al. Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension. 2010;55:48–53. 8.	 Itoga NK, Tawfik DS, Lee CK, et al. Association of blood pressure measurements with peripheral artery disease events. Circulation. 2018;138:1805– 1814. 9.	 Mehler PS, Coll JR, Estacio R, et al. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation. 2003;107:753–756. 10.	 Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst. 2000;1:18–20. 11.	 Investigators O, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547–1559. 12.	 Armstrong EJ, Chen DC, Singh GD, et al. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med. 2015;20:237–244. 13.	 Lawes CM, Vander Hoorn S, Rodgers A, et al. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–1518. 14.	 Clement DL, De Buyzere ML, Duprez DA. Hypertension in peripheral arterial disease. Curr Pharm Des. 2004;10:3615–3620. 15.	 Kennedy M, Solomon C, Manolio TA, et al. Risk factors for declining anklebrachial index in men and women 65 years or older: the Cardiovascular Health Study. Arch Intern Med. 2005;165:1896–1902. 16.	 Fudim M, Hopley CW, Huang Z, et al. Association of hypertension and arte-

rial blood pressure on limb and cardiovascular outcomes in symptomatic peripheral artery disease: the EUCLID Trial. Circ Cardiovasc Qual Outcomes. 2020;13:e006512. 5.4. Smoking Cessation for PAD 1.	 Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guideline on life-

style management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S76-S99. 2.	 Stead LF, Buitrago D, Preciado N, et al. Physician advice for smoking cessa-

tion. Cochrane Database Syst Rev. 2013;CD000165. 3.	 Patnode CD, Henderson JT, Thompson JH, et al. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the US Preventive Services Task Force. Ann Intern Med. 2015;163:608–621. 4.	 Hennrikus D, Joseph AM, Lando HA, et al. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol. 2010;56:2105–2112. 5.	 Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation. 2010;121:221–229. 6.	 Rigotti NA, Regan S, Levy DE, et al. Sustained care intervention and postdischarge smoking cessation among hospitalized adults: a randomized clinical trial. JAMA. 2014;312:719–728. 7.	 Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24:946–955. 8.	 Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation. 2014;129:28–41. 9.	 Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis. BMJ. 2012;344:e2856. 10.	 United States Public Health Service Office of the Surgeon General; National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Smoking Cessation: A Report of the Surgeon General. Washington (DC): US Department of Health and Human Services; 2020. 11.	 Mons U, Muezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: metaanalysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ. 2015;350:h1551. 12.	 Lv X, Sun J, Bi Y, et al. Risk of all-cause mortality and cardiovascular disease associated with secondhand smoke exposure: a systematic review and meta-analysis. Int J Cardiol. 2015;199:106–115. 13.	 Lu L, Mackay DF, Pell JP. Secondhand smoke exposure and risk of incident peripheral arterial disease and mortality: a Scotland-wide retrospective cohort study of 4045 non-smokers with cotinine measurement. BMC Public Health. 2018;18:348. 14.	 Ngu NL, McEvoy M. Environmental tobacco smoke and peripheral arterial disease: a review. Atherosclerosis. 2017;266:113–120. 15.	 Willigendael EM, Teijink JA, Bartelink ML, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004;40:1158–1165. 16.	 Duval S, Long KH, Roy SS, et al. The contribution of tobacco use to high health care utilization and medical costs in peripheral artery disease: a state-based cohort analysis. J Am Coll Cardiol. 2015;66:1566–1574. 17.	 Ding N, Sang Y, Chen J, et al. Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases. J Am Coll Cardiol. 2019;74:498–507. 18.	 Rigotti NA, Tindle HA, Regan S, et al. A post-discharge smoking-cessation intervention for hospital patients: Helping Hand 2 randomized clinical trial. Am J Prev Med. 2016;51:597–608. 19.	 Rose JJ, Krishnan-Sarin S, Exil VJ, et al. Cardiopulmonary impact of electronic cigarettes and vaping products: A scientific statement from the American Heart Association. Circulation. 2023;148:703–728. 20.	 Bhatnagar A, Whitsel LP, Ribisl KM, et al. Electronic cigarettes: a policy statement from the American Heart Association. Circulation. 2014;130:1418– 1436. 21.	 Bhatnagar A, Maziak W, Eissenberg T, et al. Water pipe (hookah) smoking and cardiovascular disease risk: a scientific statement from the American Heart Association. Circulation. 2019;139:e917–e936. 22.	 Hoel AW, Nolan BW, Goodney PP, et al. Variation in smoking cessation after vascular operations. J Vasc Surg. 2013;57:1338–1344; quiz 1344. e1-4. 23.	 Armstrong EJ, Wu J, Singh GD, et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg. 2014;60:1565– 1571. 24.	 Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and

weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013;309:1014–1021.

Downloaded from http://ahajournals.org by on October 7, 2026